Education
About Us
Working with TipRanks
Follow Us
Liminatus Pharma, Inc. (LIMN)
:LIMN
LIMN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.20 - $33.66
Previous CloseN/A
VolumeN/A
Average Volume (3M)767.83K
Market Cap
$119.63M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.85
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding27,064,632
10 Day Avg. Volume433,975
30 Day Avg. Volume767,826
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Liminatus Pharma News
LIMN FAQ
What was Liminatus Pharma, Inc.’s price range in the past 12 months?
Liminatus Pharma, Inc. lowest stock price was $4.20 and its highest was $33.66 in the past 12 months.
What is Liminatus Pharma, Inc.’s market cap?
Liminatus Pharma, Inc.’s market cap is $119.63M.
When is Liminatus Pharma, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Liminatus Pharma, Inc.’s earnings last quarter?
Currently, no data Available
Is Liminatus Pharma, Inc. overvalued?
According to Wall Street analysts Liminatus Pharma, Inc.’s price is currently Overvalued.
Does Liminatus Pharma, Inc. pay dividends?
Liminatus Pharma, Inc. does not currently pay dividends.
What is Liminatus Pharma, Inc.’s EPS estimate?
Liminatus Pharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Liminatus Pharma, Inc. have?
Liminatus Pharma, Inc. has 27,064,632 shares outstanding.
What happened to Liminatus Pharma, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Liminatus Pharma, Inc.?
Currently, no hedge funds are holding shares in LIMN
Liminatus Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
LIMN Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 100.0K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.92%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-100.00%
Trailing 12-Months
Company Description
Liminatus Pharma, Inc.
Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.
Liminatus Pharma (LIMN) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
Compugen
―
Assembly Biosciences
―
Lyell Immunopharma
―
Tenaya Therapeutics
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
―
Insiders
―
Mutual Funds
― Other Institutional Investors
99.73% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---